EMSP2026 Conference: Moving the needle on MS and related disorders

Berlin welcomed us with a packed room and a shared mission: building a fairer future for people living with MS, NMOSD, and MOGAD and sent us home with plenty to act on. From patient voices to policy levers, here’s a quick look back at what moved us.

The day opened with a warm welcome from DMSG, CEO, Herbert Temmes and its Chair, Judith Haas who set the stage with the conference theme. They were followed by a video message from former German President and DMSG patron Christian Wulff.

Katerina Misiura (Ukrainian MS Society) and Aida Fuentes, and opened the conference with two very different journeys: a teenage MS diagnosis that became fifteen years of advocacy, an NMO diagnosis arriving mid-motherhood, and a shared reminder that community changes the diagnosis.

The Science Got Sharper

Anke Salmen (Ruhr University Bochum) decoded the McDonald 2024 criteria, and the optic nerve officially joined the club as a fifth region. Central Vein Sign, Paramagnetic Rim Lesions, Kappa Free Light Chains, and a new “preclinical MS” category rounded out the updated toolbox, all pointing to one outcome: fewer people waiting years for answers.

We Literally Moved

Stephanie Woschek (DMSG) got the entire room moving for coordination exercises, and it was the best kind of interruption. Ten minutes of moving together beat ten more minutes of sitting still — a reminder that movement belongs in every conference agenda, and in everybody’s. Thank you, Stephanie!

Trials, Data, and the Diagnostic Gap

Paul Friedemann (Charité) made the case for clinical trials as the engine behind better diagnosis, not just better drugs — with neurofilament light chain moving from research tool to clinical ally. Bruno Stankoff (ECTRIMS), Rachel King (MSIF), and Hugo Hermantin (European Brain Council) then tackled why geography still dictates diagnostic timing in Europe, and what it would take to fix it: simplified national guidance, better-trained GPs, mobile MRI units, and EU-level prioritisation. The afternoon breakout on registries and PROs, moderated by Birgit Bauer, introduced us to the MS Iceberg – all the fatigue, anxiety, and cognitive burden that clinic visits miss, and made the case that trust is the real currency of data.

From Data to Action: Building Evidence-Based Policies

Janaki Raman Ranfarajan, Lydia Makaroff, and Jan Anders Istad made a compelling case that good policy starts with good data and good storytelling. Scientific data and policy data aren’t the same thing; getting lived experience, registries, and health economics into the same room is how MS societies secure their fair share of attention and funding. AI came up too, with a healthy dose of realism: a useful GPS, not a gamechanger, and only as fair as the data it’s trained on. The call to action was clear- share data across Europe, put patient voices at the policy table, and remember that data, done right, saves lives.

Day 1 gave us the why. Day 2 brings the how.

We will kick off with Mirjam Kottmann’s “Just Do It!”. From there, the agenda goes biology-deep: a panel on biology-driven care, followed by three hot topics the MS community can’t stop talking about — CAR-T, stem cells, and menopause & MS.

Expect another Move It! moment to shake off the morning, big conversations about the future of MS in Europe, and one last chance to drop your quiz card at reception for a shot at our quiz to win a chnace to attend the EMSP2027 conference in Portugal.

Check out the Day 2 highlights here.